CGRP In the Treatment & Prevention of Migraine - American Academy of Neurology

In 2018, the first of a new class of migraine prevention agents was FDA approved for use. This class of medications, anti-CGRP (calcitonin gene-related peptide inhibitors), now has five medications that can be used for migraine prevention. Four of these medications are CGRP monoclonal antibodies, and one is a CGRP receptor antagonist. There are two medications for acute use, both of which are CGRP receptor antagonists. We aim in this video to give an overview of this class of medications, to include dosing and use in both prevention and acute migraine treatment. To view more NeuroBytes visit http://www.AAN.com/NeuroBytes Music: "Inspired" by Kevin MacLeod, Incomptech (https://incompetech.filmmusic.io/) Connect with the AAN Visit the American Academy of Neurology at https://www.aan.com Twitter: https://bit.ly/1orvPet Instagram: http://bit.ly/2eVgsz4 Facebook: http://bit.ly/2feMxW4 LinkedIn: http://bit.ly/22mKzkM